Quanterix (NASDAQ:QTRX) and Valeritas (OTCMKTS:VLRXQ) Head to Head Comparison

Valeritas (OTCMKTS:VLRXQ) and Quanterix (NASDAQ:QTRX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, valuation, earnings, risk and dividends.

Analyst Recommendations

This is a summary of current ratings and price targets for Valeritas and Quanterix, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valeritas	0	0	0	0	0.00
Quanterix	1	2	0	0	1.67

Quanterix has a consensus price target of $4.00, indicating a potential upside of 0.76%. Given Quanterix’s stronger consensus rating and higher possible upside, analysts clearly believe Quanterix is more favorable than Valeritas.

Profitability

This table compares Valeritas and Quanterix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Valeritas	N/A	N/A	N/A
Quanterix	-71.86%	-23.92%	-17.66%

Earnings and Valuation

This table compares Valeritas and Quanterix”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valeritas	N/A	N/A	N/A	N/A	N/A
Quanterix	$144.74 million	1.29	-$107.15 million	($2.36)	-1.68

Valeritas has higher earnings, but lower revenue than Quanterix.

Institutional and Insider Ownership

86.5% of Quanterix shares are owned by institutional investors. 1.0% of Valeritas shares are owned by insiders. Comparatively, 1.5% of Quanterix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Quanterix beats Valeritas on 5 of the 8 factors compared between the two stocks.

About Valeritas

Valeritas Holdings, Inc., a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States. The company offers V-Go, a wearable insulin delivery device for basal-bolus therapy. It also develops V-Go Prefill that is in the design-development stage for eliminating the device-filling process and the need for EZ fill refrigeration for patients with Type 2 diabetes; and V-Go SIM for real-time tracking information of basal and bolus dosing utilization. The company sells V-Go to third-party wholesalers and medical supply distributors. Valeritas Holdings, Inc. was founded in 2006 and is headquartered in Bridgewater, New Jersey.

About Quanterix

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.